SMMT slides nearly 15% as technical weakness follows FDA rejection on BLA
Summit Therapeutics Inc. (SMMT) dropped 14.68% today after the FDA issued a Complete Response Letter on its ivonescimab BLA, which delayed a key regulatory milestone for the company. The severity of the move is reinforced by sustained downside momentum, with SMMT trading below its 20-, 50-, and 200-day moving averages and prices pinned near intraday lows.
Highlights
- The FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab application in NSCLC, delaying potential U.S. approval.
- Summit Therapeutics lost its first-mover advantage in the PD-1xVEGF bispecific antibody category and analyst price targets were adjusted after the FDA response.
- Shares of Summit Therapeutics trade below key moving averages with persistent selling pressure and a projected five-day range of $10.03 to $14.27.
Analyst targets cut as FDA letter erodes SMMT’s drug lead
On November 15, 2026, the FDA issued a Complete Response Letter regarding Summit Therapeutics' Biologics License Application for ivonescimab in combination with platinum-based chemotherapy for previously treated NSCLC patients. This decision delayed potential U.S. approval and impacted Summit Therapeutics’ first-mover advantage in the PD-1xVEGF bispecific antibody drug class. No insider trading activity has been reported in recent months. Analyst price targets were adjusted following the FDA response.
Sustained downside and oversold signals mark technical landscape
SMMT is trading below its 20-day ($15.76), 50-day ($16.41), and 200-day ($16.15) moving averages, reflecting persistent pressure across all observed timeframes. The nearest resistance is at $13.28, while support is marked at today's low of $11.94. Momentum indicators point to weakness: the MACD signals selling pressure, ADX suggests a lack of strong trend, and RSI is neutral. Both the Stochastic RSI and CCI are in oversold zones, indicating potential selling exhaustion and the possibility of a rebound. Bull/Bear Power is negative, confirming sellers dominate intraday momentum. Price action is near session lows after opening with a downside gap, and volatility is elevated at 11.22%, underscoring negative momentum.
Earlier, analysts noted that Summit Therapeutics remained under technical pressure with a firmly negative outlook tied to regulatory developments and price declines. The latest FDA Complete Response Letter deepens this trend, and traders should monitor for stabilization or further breakdown as Summit's shares hover near critical support in a volatile environment.